Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Files An 8-K Regulation FD DisclosureItem 7.01
Aquinox Pharmaceuticals, Inc. (the “Company”) has prepared investor presentation materials with information about the Company, which it intends to use as part of investor presentations. A copy of the investor presentation materials to be used by management for presentations is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
This information contained in this Current Report on Form 8-K, including the attached Exhibit 99.1, shall be deemed “furnished” and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference to such filing.
| Item 7.01. | Financial Statements and Exhibits. |
(d) Exhibits
|
Number |
Description |
| 99.1 | Presentation of Aquinox Pharmaceuticals, Inc. |
AQUINOX PHARMACEUTICALS, INC ExhibitEX-99.1 2 d519342dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Aquinox R&D Day February 9,…To view the full exhibit click here
About Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP)
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. Its primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells. The Company’s product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial.